Clinical Trials Using Margetuximab
Clinical trials are research studies that involve people. The clinical trials on this list are studying Margetuximab. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2 / 3 Trial in HER2+ Gastric / GEJ Cancer (MAHOGANY)
This is a Phase 2 / 3, randomized, open-label study for the treatment of patients with HER2-positive Gastric cancer (GC) or Gastroesophageal Junction (GEJ) cancer to determine the efficacy of margetuximab combined with INCMGA00012 (also known as MGA012) (Cohort A) and margetuximab combined with INCMGA00012 or MGD013 and chemotherapy compared to trastuzumab combined with chemotherapy (Cohort B).
Location: 17 locations
Paclitaxel and Pertuzumab with Margetuximab or Trastuzumab for the Treatment of HER2-Positive Stage II-III Invasive Breast Cancer, The MARGOT Trial
This phase II trial investigates how well paclitaxel and pertuzumab with margetuximab or trastuzumab works in treating patients with HER2-positive stage II-III invasive breast cancer. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pertuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Trastuzumab and margetuximab are both forms of targeted therapy because they attach themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab and margetuximab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. This trial is being done to determine how well HER2-positive breast cancer responds to pre-operative treatment using one of two different combination of drugs as a treatment for this diagnosis.
Location: 10 locations
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD013 and establish the maximum tolerated dose (MTD) of MGD013. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of MGD013 will also be assessed.
Location: 9 locations